Clinical Characteristics of Patients Who Received NK Cell Therapy

UPNCharacteristics at DiagnosisHLA StatusDonor KIR– Recipient HLA MismatchPeak NK Cell ChimerismAdoptive NK Cell TransferDays from NK cell transplant to relapse
Age at diagnosis (Years)SexKaryotypeBwC%DayNK Cells− (106/kg)
11.1Mt(11;19)6/6C1/C1CD158a, CD158e10716.5
21.6F+ 4,t(6;11),+der(6)t(6;11),+ 8,+ 13,+ 194/6C2/C2CD158b11411.5629
32.1Mt(9;11),+X,+ 7,+ 84/6C2/C2CD158b2612.4
410.2F46,XX4/6C2/C2CD158b4128.2527
51.2Ft(1;22),+ 2,+ 8,+ 21,+der(22)t(1;22)4/6C1/C1CD158a23746.9617
615.4F46,XX6/6C1/C2CD158e18133.6
71.2Ft(11;19),t(12;19)4/6C2/C2CD158b2836.9
80.1FN/A6/6C1/C2CD158e1431444.3
90.5Fder(10)4/6C1/C1CD158a15726.8
104.5M46,XY6/6C1/C1CD158a, CD158e16714.8300†
112.1Mt(1;11),+ 96/6C1/C1CD158a, CD158e12725.7
1213.2F+ 8,t(11;19),+ 17,+ 196/6C1/C1CD158a, CD158e11576.7228
1315.3F+ 214/6C1/C1CD158a14125.2
1412.4Mt(1;2),del(9),-12,t(17;20),der(18)4/6C1/C1CD158a378.8186†
151.6M+ 8,t(9;11;14)4/6C2/C2CD158b0712.5
1614.3Fins(10;11),ins(17;11)4/6C1/C1CD158a2275.7231†
170.7Mt(5;6)4/6C2/C2CD158b322142.4
183.0M46,XY4/6C1/C1CD158a0762.6
194.0M46,XY4/6C1/C1CD158a4712.4
2012.2M+X,+ 9,+ 11,+ 14,+ 206/6C1/C2CD158e1179.0367
219.2M46,XY6/6C1/C1CD158a, CD158e110719.3

Abbreviations: CNS central nervous system, HLA human leukocyte antigen, KIR killer immunoglobulin-like receptor, N/A not available, NK natural killer, UPN unique patient number. Deceased